Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: Purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma

Bone Marrow Transplantation

Volumn 29, Issue 9, 2002, Pages 731-736

  Handgretinger, R ^a   Lang, P ^a   Ihm, K ^a   Schumm, M ^a   Geiselhart, A ^a   Koscielniak, E ^b   Hero, B ^c   Klingebiel, T ^d   Niethammer, D ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b OLGAHOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

CD34 positive selection; Neuroblastoma; Peripheral stem cells; Purging

Indexed keywords

ANTIGENS, CD34; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; HEMATOPOIESIS; HUMANS; IMMUNOMAGNETIC SEPARATION; INFANT; MALE; MYELOABLATIVE AGONISTS; NEOPLASM CIRCULATING CELLS; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

(3 IODOBENZYL)GUANIDINE I 131; ANTINEOPLASTIC AGENT; CARBOPLATIN; CD34 ANTIGEN; CISPLATIN; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; IFOSFAMIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW PURGING; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CELL ISOLATION; CELL SELECTION; CHILD; CLINICAL ARTICLE; CONTAMINATION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT FAILURE; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; MALE; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PURIFICATION; STEM CELL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TIME; TREATMENT OUTCOME;

EID: 85047698455     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703536     Document Type: Article

References (32)

1. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma
2. Clonogenicity of circulating neuroblastoma cells: Implications regarding peripheral blood stem cell transplantation
3. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
4. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
5. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads
6. [Evaluation of a modified immunomagnetic procedure for the purging of neuroblastoma cells from bone marrow]
7. Highly purified CD34-positive cells reconstitute hematopoiesis
8. Positive selection and transplantation of peripheral CD34+ progenitor cells: Feasibility and purging efficacy in pediatric patients with neuroblastoma
9. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma
10. CD34+ selection: The basic component for graft engineering
11. + progenitors for autologous and allogeneic transplantation in children
12. + progenitor cells highly purified by magnetic-activated cell sorting
13. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device
14. Treatment of advanced neuroblastoma: The European experience
15. Neuroblastoma: Current drug therapy recommendations as part of the total treatment approach
16. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering
17. Treatment of neuroblastoma stage 4 with 1311-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study
18. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch 14.18 in patients with neuroblastoma
19. Neuroblastoma: Biology and therapy
20. Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry
21. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
22. Gene marking to improve the outcome of autologous bone marrow transplantation
23. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year
24. Detection of circulating melanoma cells by immunomagnetic cell sorting
25. Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia
26. Monoclonal antibodies with neuroblastoma specificity: A flow cytometric analysis of cross-reactivity with CD34+ hematopoietic stem cells
27. Transplantation of megadoses of purified haploidentical stem cells
28. Neuroblastoma cells can express the hematopoietic progenitor cell antigen CD34 as detected at surface protein and mRNA level
29. AC133, a novel marker for human hematopoietic stem and progenitor cells
30. CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors
31. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
32. Monoclonal antibody-based therapy for neuroblastoma